Allergic Rhinitis Treatment Market By Disease Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Allergic Rhinitis Treatment Market
Allergic Rhinitis Treatment Market: By Disease Type (Seasonal Allergic Rhinitis, Perenial Allergic Rhinitis) By Treatment Drugs Type (Antihistamines, Intranasal corticosteroids, Immunotherapies, Decongestants, and Others) & Geography-Forecast (2016-2021)
Report Code : HCR 0111
Updated Date: 15 March, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
Allergic rhinitis is commonly known as Hay fever, caused by some of the typical allergens namely pollen, grass, dust, animal dander, cat saliva and mold. Apart from this common allergens, some of the other major factors responsible for the disease are cigarette smoke, chemicals, cold temperatures, humidity, wind, air pollution, hairspray, perfumes & colognes, wood smoke, and fumes. This is the most common allergic disease found in majority of the countries with a prevalence range of between 2 to 40% in various countries across the globe.  Allergic rhinitis refers to a chronic inflammatory disease affecting the nasal cavity identified by some of the common symptoms such as Nasal itching, sore throat, runny or blocked nose, and sneezing are some of the characteristic symptoms of allergic rhinitis.

Globally demand for allergic rhinitis treatment market is driven by factors such as increasing awareness amongst people about disease and increasing number of respiratory problems related cases due to increasing pollution and tobacco consumption.

This report identifies the allergic rhinitis treatment market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to allergic rhinitis treatment market.

Allergic Rhinitis Treatment Market

Globally demand for allergic rhinitis treatment is expected to witness growth in the upcoming future due to increasing respiratory disease globally. North America represents the highest market share in the global allergic rhinitis treatment market as reported cases for allergic rhinitis is highest in the U.S. followed by Europe with the second highest market share amongst all the major regions.
  • This report on allergic rhinitis treatment has been divided based on disease type, which is segmented as: Perennial allergic rhinitis and Seasonal allergic rhinitis
  • Allergic rhinitis treatment market is further also segmented based on the available treatments which includes major treatment namely: Antihistamines, Intranasal corticosteroids, Immunotherapies, Decongestants and others
  • This report has been further segmented into major regions, which includes detailed analysis of each region such as: North America, Europe, Asia-Pacific (APAC), and Rest of the World (RoW) covering all the major country level markets in each of the region.

This report identifies all the major companies operating in the Allergic Rhinitis market. Some of the major companies’ profiles in detail are as follows:
  • GlaxoSmithKline
  • Sanofi
  • AstraZeneca
  • Meda Pharmaceuticals
  • Dr Reddy's Laboratories
1. Allergic Rhinitis Treatment – Market Overview
2. Executive Summary
Allergic Rhinitis Treatment Market Landscape
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Allergic Rhinitis Treatment – Market Forces
   4.1. Drivers
      4.1.1. Increasing number of tobacco consumers globally
      4.1.2. Increasing number of respiratory diseases cases globally
   4.2. Restraints
      4.2.1. Lower awareness amongst large part of human population
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Allergic Rhinitis Treatment Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Global Allergic Rhinitis Treatment Market - By Disease Type 
   6.1. Seasonal Allergic Rhinitis
   6.2. Perenial Allergic Rhinitis
7. Global Allergic Rhinitis Treatment Market - By Treatment Drugs Type
   7.1. Antihistamines
   7.2. Intranasal corticosteroids
   7.3. Immunotherapies
   7.4. Decongestants
   7.5. Others
8. Global Allergic Rhinitis Treatment Market - By Geography 
   8.1. Europe
      8.1.1. Germany
      8.1.2. France
      8.1.3. Italy
      8.1.4. Spain
      8.1.5. Russia
      8.1.6. U.K.
      8.1.7. Rest of Europe
   8.2. Asia Pacific
      8.2.1. China
      8.2.2. India
      8.2.3. Japan
      8.2.4. South Korea
      8.2.5. Rest of Asia-Pacific
   8.3. North America
      8.3.1. U.S.
      8.3.2. Canada
      8.3.3. Mexico
   8.4. Rest of the World (RoW)
      8.4.1. Brazil
      8.4.2. Rest of RoW
9. Allergic Rhinitis Treatment – Market Entropy
   9.1. Expansion
   9.2. Technological Developments
   9.3. Merger & Acquisitions, and Joint Ventures
   9.4. Supply- Contract
10. Company Profiles
   10.1. GlaxoSmithKline
      10.1.1. Introduction
      10.1.2. Financials
      10.1.3. Key Insights
      10.1.4. Key Strategy
      10.1.5. Product Portfolio
      10.1.6. SWOT Analysis
   10.2. Sanofi
      10.2.1. Introduction
      10.2.2. Financials
      10.2.3. Key Insights
      10.2.4. Key Strategy
      10.2.5. Product Portfolio
      10.2.6. SWOT Analysis
   10.3. AstraZeneca
      10.3.1.  Introduction
      10.3.2. Financials
      10.3.3. Key Insights
      10.3.4. Key Strategy
      10.3.5. Product Portfolio
      10.3.6. SWOT Analysis
   10.4. Meda Pharmaceuticals
      10.4.1. Introduction
      10.4.2. Financials
      10.4.3. Key Insights
      10.4.4. Key Strategy
      10.4.5. Product Portfolio
      10.4.6. SWOT Analysis
   10.5. Dr Reddy's Laboratories
      10.5.1. Introduction
      10.5.2. Financials
      10.5.3. Key Insights
      10.5.4. Key Strategy
      10.5.5. Product Portfolio
      10.5.6. SWOT Analysis
   10.6. Pfizer
      10.6.1. Introduction
      10.6.2. Financials
      10.6.3. Key Insights
      10.6.4. Key Strategy
      10.6.5. Product Portfolio
      10.6.6. SWOT Analysis
   10.7. Novartis
      10.7.1. Introduction
      10.7.2. Financials
      10.7.3. Key Insights
      10.7.4. Key Strategy
      10.7.5. Product Portfolio
      10.7.6. SWOT Analysis
   10.8. Sun Pharmaceuticals
      10.8.1. Introduction
      10.8.2. Financials
      10.8.3. Key Insights
      10.8.4. Key Strategy
      10.8.5. Product Portfolio
      10.8.6. SWOT Analysis
   10.9. UCB S.A.
      10.9.1. Introduction
      10.9.2. Financials
      10.9.3. Key Insights
      10.9.4. Key Strategy
      10.9.5. Product Portfolio
      10.9.6. SWOT Analysis
   10.10. Atopix Therapeutics
      10.10.1. Introduction
      10.10.2. Financials
      10.10.3. Key Insights
      10.10.4. Key Strategy
      10.10.5. Product Portfolio
      10.10.6. SWOT Analysis
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix

   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Expert Insights
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports